Suppliers / Jiangsu Weiqida Pharmaceutical

Jiangsu Weiqida Pharmaceutical

China Updated 9 July 2026

Jiangsu Weiqida Pharmaceutical is an API manufacturer based in China. It holds one active US drug master file and 3 valid CEPs across a filed portfolio of 3 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 21 March 2025 as VAI.

1
active US DMFs
3
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 21 March 2025 VAI US FDA
  • 15 December 2017 VAI US FDA
  • 30 April 2014 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Nantong City, China Not on file
China, China 3008245746

What they file, and where

Molecule Regulators Docs
Azithromycin EDQM, SFDA (Saudi Arabia), US FDA 3
Abacavir EDQM 1
Nebivolol EDQM 1

Also appears on these molecule pages

Abacavir API Azithromycin API Nebivolol API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Jiangsu Weiqida Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 21 March 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates